Arrowhead Pharmaceuticals Reports Fiscal 2025 First Quarter Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/19/2026
- Wall St recovers as yields ease; Moderna lifts healthcare stocks
- U.S. Treasury doubles buyback operation size for long-dated bonds
- Marvell shares jump after giving Google warrants amid custom chip deal
- Nvidia credit risk gauge hits new peak as SoftBank readies record bond issue
- Deutsche Bank calls Treasury buyback doubling similar to ’operation twist’
- Marvell issues Google warrant tied to custom chip deal
- Tech selloff weighs down Wall Street as bond yields climb
- Lowe's Cos. (LOW) Tops Q2 EPS by 17c, Misses on Revenue; Offers Fy27 Guidance
- Nvidia or Sandisk? BofA reveals which stock is under-owned and which is crowded
- Francisco Partners to acquire Weave Communications for $650M
Chardan Capital Markets Reiterates Buy Rating on Arrowhead Pharma (ARWR)
February 11, 2025 7:46 AM ESTChardan Capital Markets analyst Keay Nakae reiterated a Buy rating and $60.00 price target on Arrowhead Pharma (NASDAQ: ARWR)
The analyst comments "The company is currently evaluating plozasiran in three other phase III studies: SHASTA-3 and SHASTA-4 in adults with SHTG (currently enrolling), and MUIR-3 in adults... More
